Balixafortide is under clinical development by Spexis and currently in Phase I for Pancreatic Ductal Adenocarcinoma. According to GlobalData, Phase I drugs for Pancreatic Ductal Adenocarcinoma does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Balixafortide LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Balixafortide overview

Balixafortide is under development for the treatment of cancers including metastatic triple negative breast cancer and other solid and hematological tumors including b cell lymphoma, mantle cell lymphoma, chronic lymphocytic leukemia, and marginal zone lymphoma, HER2 negative breast cancer, metastatic prostate cancer, coronavirus disease 2019, rare diseases and pancreatic ductal adenocarcinoma. The therapeutic candidate is administered through the intravenous, inhalation and subcutaneous route. It acts by targeting C-X-C chemokine receptor type 4 (CXCR-4). The drug candidate is based on protein epitope mimetics (PEM) technology. It was under development for the treatment of myocardial infarction, hematopoietic stem cell transplantation, asthma and inflammation and HER2 negative recurrent or metastatic breast cancer.

Spexis overview

Spexis (Spexis) formerly Polyphor Ltd, is a biopharmaceutical company developing immuno-oncology medicines and antibiotics for treatment of cancer and respiratory diseases. The company’s lead product candidate includes balixafortide (POL6326) an antagonist chemokine receptor CXCR4 for treatment of metastatic breast cancer; inhaled murepavadin a novel class outer membrane protein targeting antibiotic (OMPTA) to treat pseudomonas aeruginosa in cystic fibrosis; POL6014 an inhaled inhibitor of neutrophil elastase for the treatment of cystic fibrosis and other severe lung diseases. It has also discovered POL7306 a novel class of antibiotics the outer membrane protein targeting antibiotics (OMPTA) to treat infections caused by gram-negative bacteria including mdr strains. Spexis is headquartered in Allschwil, Switzerland.

For a complete picture of Balixafortide’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.